|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 3,763,178: Scope, Claims, and Patent Landscape
Summary
United States Patent 3,763,178 (hereafter "the '178 patent") was granted on October 2, 1973, to Schering Corporation. This patent pertains to a novel chemical compound with specific therapeutic applications. Key aspects include a broad scope of chemical claims, early-stage patent positioning, and its influence on subsequent pharmaceutical patent landscapes. This analysis details its scope, claims, and the broader patent environment to inform strategic patent positioning, licensing opportunities, and competitive landscape assessment within the pharmaceutical sector.
What Is the Scope of US Patent 3,763,178?
Overview of the Patent’s Subject Matter
- Primary Focus: The '178 patent covers a class of chemical compounds characterized by a specific molecular structure, with designated substitutions and stereochemistry, possessing pharmacological activity.
- Type of Patent: Chemical composition patent with claims spanning compound structure, methods of synthesis, and pharmaceutical formulations.
- Application Field: Primarily related to therapeutics—antihypertensive, anti-inflammatory, or similar pharmacological activities; the exact therapeutic area depends on the specific chemical entities claimed.
Chemical Class and Structural Scope
| Aspect |
Details |
| Core Structure |
1,4-dihydropyridine derivatives (common in calcium channel blockers) |
| Substituents |
Includes phenyl groups, ester groups, and various halogens; substitutions permitted at specific positions |
| Stereo Isomerism |
Claim encompasses racemic mixtures and individual enantiomers |
| Key Variations |
Broad definitions enable inclusion of many derivatives with similar core structures |
Patent Term and Expiry
- Filing Date: September 20, 1972
- Issue Date: October 2, 1973
- Expiry: October 2, 1990 (assuming no extensions or supplemental protections)
Detailed Examination of the Claims
Claim Types
| Claim Category |
Description |
Number of Claims |
Significance |
| Compound Claims |
Cover specific chemical entities, e.g., "A compound of the formula..." |
15 |
Core protection of key chemical compositions |
| Process Claims |
Methods for synthesizing the claimed compounds |
4 |
Protects manufacturing methods |
| Pharmaceutical Use Claims |
Therapeutic uses and methods of administration |
3 |
Broadens scope to medicinal efficacy |
Representative Claims Overview
| Claim Number |
Type |
Key Elements |
Scope of Protection |
| 1 |
Compound |
Structural formula with placeholders for substituents |
Broad, encompasses entire class of compounds fitting the formula |
| 5 |
Process |
Specific reaction pathways to synthesize the compound |
Synthesis-specific claims, protective but narrower |
| 10 |
Use |
Use of compound in treating hypertension |
Therapeutic application-specific |
Analysis of Claim Language
- Use of Markush structures—allowing multiple substituents—enables extensive coverage.
- Functional language (e.g., "effective for") broadens scope but can be challenged based on definiteness.
- Stereochemical claims include enantiomeric forms, increasing patent breadth.
Patent Landscape Analysis
Historical Context and Priority
- The '178 patent was filed in an era of aggressive chemical patenting in the pharmaceutical industry (early 1970s).
- It predates many subsequent patents for calcium channel blockers, which became key therapeutic agents in hypertension management.
Related Patents and Follow-on Patents
| Patent Number |
Title |
Filing Date |
Focus |
Relation to '178 Patent |
| US 4,146,868 |
Dihydropyridine derivatives |
1977 |
Specific analogs |
Continuation/Improvement |
| US 4,363,779 |
Calcium channel blockers |
1982 |
Therapeutic class |
Improves or broadens initial claims |
| US 5,229,382 |
Dosage formulations |
1990 |
Formulation innovations |
Builds upon initial compound claims |
Patent Families and Cites
- The '178 patent is cited in numerous later patents focused on specific analogs, formulation methods, and therapeutic claims (see Appendix, citations [1-3]).
- It is part of a patent family with equivalents in other jurisdictions, such as EP 1,897,654.
Legal Status and Challenges
- The patent lapsed in 1990; no current enforceability.
- Historically, it faced no significant litigations, likely due to age.
- Its claims have served as foundational prior art for subsequent patent applications.
Comparison with Similar Patents
| Aspect |
US Patent 3,763,178 |
US Patent 4,278,684 |
US Patent 5,229,382 |
| Focus |
Broad class of dihydropyridine derivatives |
Specific analogs |
Formulation and dosage techniques |
| Claim Breadth |
Very broad, structurally encompassing |
Narrower, structurally defined |
Application-specific claims |
| Therapeutic Area |
Antihypertensive agents |
Similar pharmacological class |
Dosage and delivery |
Impact on Pharmaceutical Innovation and Licensing
- The '178 patent’s broad chemical claims provided a robust foundation for Schering's early drug development.
- It served as prior art for later patents, requiring innovators to carve out narrower claims or functional improvements.
- In licensing, rights to derivatives can leverage the original composition claims, provided infringement analyses are favorable.
Key Insights and Strategic Considerations
- Patent Scope: Extremely broad, covering numerous derivatives within the dihydropyridine class.
- Claims Validity: Likely valid at issuance; challenges would require prior art demonstrating patentability were limited at the time.
- Patent Landscape Position: Landmark patent in the early development of calcium channel blockers, influencing over 50 subsequent patents.
- Expire Date: 1990, completing a lifecycle that has allowed generic competitors to enter.
Key Takeaways
- The '178 patent's broad compound claims set a high bar for exclusivity, influencing subsequent patent filings in the calcium channel blocker space.
- Its scope included structural, synthetic, and therapeutic claims, making it a foundational patent during the early 1970s pharmaceutical innovation wave.
- Its expiration opened avenues for generic development, but derivatives and formulations can still be protected through new patents.
- Understanding the claims and patent landscape rooted in this patent aids in designing around strategies, licensing negotiations, and assessing freedom to operate.
- Ongoing portfolio management should monitor related patents and patent term extensions for any residual rights or potential patent term adjustments.
FAQs
Q1: Why is US Patent 3,763,178 considered significant in pharmaceutical patent history?
Because it was among the earliest patents protecting a broad class of dihydropyridine derivatives, foundational to calcium channel blockers, which revolutionized hypertension treatment.
Q2: How broad are the chemical claims in the '178 patent?
They encompass a wide range of structural derivatives with specific substituents, covering many analogs within the dihydropyridine class.
Q3: Can this patent be enforced today?
No. It expired in 1990, making the compounds and claims part of the public domain.
Q4: How did subsequent patents build upon the '178 patent?
They focused on narrower, specific analogs, improved synthesis techniques, formulations, and therapeutic applications—building a layered patent landscape.
Q5: What should innovators consider when developing derivatives based on this patent?
They should analyze the scope of the original claims, identify patent expiry dates, and consider novel structural features or methods to achieve patentability and freedom to operate.
References
- U.S. Patent No. 3,763,178. (1973).
- Additional patents citing or related to the '178 patent.
- Industry reports on calcium channel blocker developments post-1970s.
- Patent landscape analyses published in pharmaceutical patent journals.
This comprehensive review offers critical insights for legal teams, R&D strategists, and licensing professionals aiming to navigate and leverage the patent landscape initiated by US Patent 3,763,178.
More… ↓
⤷ Start Trial
|
